2. Search Result
Search Result
Results for "

apelin receptor

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

21

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109111
    Azelaprag

    AMG 986

    		 Apelin Receptor (APJ) Others
    Azelaprag (Example 263.0) is an apelin receptor agonist agent candidate .
    Azelaprag
  • HY-147751
    APJ receptor agonist 6

    		Arrestin Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 6 (compound 9) is a potent APJ (apelin receptor) agonist, with Ki of 1.3 μM. APJ receptor agonist 6 has EC50 values of 0.070 , 0.097, and 0.063 μM for calcium, cAMP, and β-arrestin, respectively .
    APJ receptor agonist 6
  • HY-P1944
    Apelin-13

    		Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13
  • HY-145284
    APJ receptor agonist 4

    		Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease .
    APJ receptor agonist 4
  • HY-145285
    APJ receptor agonist 5

    		Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 5 (compound 3) is a potent and orally active agonist of apelin receptor (APJ) with an EC50 of 0.4 nM. APJ receptor agonist 5 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 5 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 5 leads to improved cardiac function and can be used for researching the HF disease .
    APJ receptor agonist 5
  • HY-P2537
    Apelin-12

    		HIV Apelin Receptor (APJ) Others
    Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect .
    Apelin-12
  • HY-P1033
    [Pyr1]-Apelin-13
    1 Publications Verification

    [pGlu1]-apelin-13

    		 Apelin Receptor (APJ) Cardiovascular Disease
    [Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.
    [Pyr1]-Apelin-13
  • HY-P3162
    (Ala13)-Apelin-13

    		Apelin Receptor (APJ) Cardiovascular Disease
    (Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway .
    (Ala13)-Apelin-13
  • HY-P3162A
    (Ala13)-Apelin-13 TFA

    		Apelin Receptor (APJ) Cardiovascular Disease
    (Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway .
    (Ala13)-Apelin-13 TFA
  • HY-P1944A
    Apelin-13 TFA
    5 Publications Verification

    		 Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13 TFA
  • HY-103080
    CMF019

    		Apelin Receptor (APJ) Cardiovascular Disease
    CMF019 is a potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents . Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin .
    CMF019
  • HY-P1065
    Apelin-36(rat, mouse)

    		Apelin Receptor (APJ) HIV Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ .
    Apelin-36(rat, mouse)
  • HY-P1066
    Apelin-17(human, bovine)

    		Apelin Receptor (APJ) HIV Infection
    Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-17(human, bovine)
  • HY-P1064
    Apelin-36(human)

    		Apelin Receptor (APJ) HIV Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-36(human)
  • HY-P1064A
    Apelin-36(human) TFA

    		HIV Apelin Receptor (APJ) Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-36(human) TFA
  • HY-P1066A
    Apelin-17(human, bovine) TFA

    		HIV Apelin Receptor (APJ) Infection
    Apelin-17(human, bovine) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) TFA binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-17(human, bovine) TFA
  • HY-P1065A
    Apelin-36(rat, mouse) TFA

    		HIV Apelin Receptor (APJ) Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ .
    Apelin-36(rat, mouse) TFA
  • HY-126293
    Apelin agonist 1

    		Apelin Receptor (APJ) Cardiovascular Disease
    Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the APJ (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0 .
    Apelin agonist 1
  • HY-139485
    BMS-986224

    		Apelin Receptor (APJ) Cardiovascular Disease
    BMS-986224 is a potent, selective and orally active APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr 1) apelin-13. BMS-986224 has the potential for the research of heart failure .
    BMS-986224
  • HY-133036
    APJ receptor agonist 1

    		Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC50s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure .
    APJ receptor agonist 1
  • HY-108003
    MM 07

    		Apelin Receptor (APJ) Cardiovascular Disease
    MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.
    MM 07
  • HY-P2196
    ELA-32(human)

    		Apelin Receptor (APJ) Cardiovascular Disease
    ELA-32 (human) is a potent critical cardiac developmental peptide that acts through the G-protein–coupled apelin receptor .
    ELA-32(human)
  • HY-125976
    ML233

    		Apelin Receptor (APJ) Cardiovascular Disease
    ML233 is a non-peptide based potent apelin receptor (APJ) agonist (EC50=3.7 μM). ML233 displays >21-fold selective over the closely related angiotensin 1 (AT1) receptor (>79 μM) .
    ML233
  • HY-P2197
    ELA-11(human)

    		Apelin Receptor (APJ) Arrestin Inflammation/Immunology
    ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pKi of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .
    ELA-11(human)
  • HY-P2249
    ELA-21 (human)

    		Arrestin Apelin Receptor (APJ) Cardiovascular Disease
    ELA-21 (human) is an apelin receptor agonist with a pKi of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways .
    ELA-21 (human)
  • HY-P2106
    Elabela(19-32)
    3 Publications Verification

    		 Arrestin Apelin Receptor (APJ) Cardiovascular Disease
    Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .
    Elabela(19-32)
  • HY-P2106A
    Elabela(19-32) TFA
    3 Publications Verification

    		 Apelin Receptor (APJ) Arrestin Cardiovascular Disease
    Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .
    Elabela(19-32) TFA
  • HY-P2197A
    ELA-11(human) TFA

    		Apelin Receptor (APJ) Inflammation/Immunology
    ELA-11(human) TFA is a high affinity apelin receptor agonist (Ki=14 nM). ELA-11(human) TFA is a bioactive fragment of ELA-32. ELA-11(human) TFA inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.
    ELA-11(human) TFA
  • HY-122197
    ML339

    		CXCR Apelin Receptor (APJ) Arrestin Cancer
    ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 has no inhibitory effect on CXCR5，CXCR4，CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research .
    ML339
  • HY-P2196A
    ELA-32(human) TFA

    		Apelin Receptor (APJ) Cancer
    ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC50=0.27 nM; Kd=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.
    ELA-32(human) TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: